Welcome!

News Feed Item

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

 

Summary

 

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

 

For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.

 

Scope

 

- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of drug performance.

- Obtain sales forecast for drugs from 2012-2022 in India.

1 Table of Contents

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Symptoms 16

3.3 Prognosis 17

3.4 Quality of Life 18

4 Disease Management 19

4.1 Treatment Overview 20

4.2 India 25

4.2.1 Diagnosis 25

4.2.2 Clinical Practice 25

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles - Major Brands 29

5.3.1 Remicade (infliximab) 29

5.3.2 Other Marketed Products 35

6 Opportunity and Unmet Need 36

6.1 Overview 36

6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37

6.3 More Therapies for Anti-TNF-Refractory Patients 38

6.4 Unmet Needs Gap Analysis 39

6.5 Targeted Therapies 40

6.6 Predictive Tools for Early Diagnosis and Treatment 41

7 Pipeline Assessment 42

7.1 Overview 42

7.2 Promising Drugs in Clinical Development 42

7.3 Other Late-Stage Pipeline Products 44

7.3.1 Cx601 44

7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46

8 Market Outlook 51

8.1 Global Markets 51

8.1.1 Drivers and Barriers - Global Issues 51

9 India 56

9.1 Forecast 56

9.2 Key Events 58

9.3 Drivers and Barriers 59

9.3.1 Driver: Continued investment in the national healthcare system and services 59

9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59

9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60

9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60

9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61

10 Appendix 62

10.1 Bibliography 62

10.2 Abbreviations 67

10.3 Methodology 71

10.4 Forecasting Methodology 71

10.4.1 Diagnosed CD Patients 71

10.4.2 Percent Drug-Treated Patients 72

10.4.3 Drugs Included in Each Therapeutic Class 72

10.4.4 General Pricing Assumptions 72

10.4.5 Individual Drug Assumptions 74

10.4.6 Generic Erosion 74

10.5 Physicians and Specialists Included in This Study 75

10.6 Primary Research - Prescriber Survey 76

10.7 About the Authors 77

10.7.1 Author/Reviewer 77

10.7.2 Global Head of Healthcare 77

10.8 About GlobalData 78

10.9 Disclaimer 78

 

1.1 List of Tables

 

Table 1: Symptoms of CD 17

Table 2: Treatment Guidelines for CD 21

Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23

Table 4: Leading Branded Drugs Used to Treat CD 29

Table 5: Product Profile - Remicade 31

Table 6: Remicade SWOT Analysis, 2013 34

Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35

Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37

Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40

Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42

Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43

Table 12: Product Profile - Cx601 45

Table 13: Cx601 SWOT Analysis, 2013 46

Table 14: Product Profile - RHB-104 48

Table 15: RHB-104 SWOT Analysis, 2013 50

Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51

Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57

Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58

Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59

Table 20: Physicians Surveyed, By Country 76

 

1.2 List of Figures

 

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13

Figure 2: Potential Biologic Drug Targets for CD 16

Figure 3: Patient Care Path for CD 22

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43

Figure 5: Sales for CD in India by Drug Class, 2012-2022 58

 

 

To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
SYS-CON Events announced today that Secure Channels will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The bedrock of Secure Channels Technology is a uniquely modified and enhanced process based on superencipherment. Superencipherment is the process of encrypting an already encrypted message one or more times, either using the same or a different algorithm.
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?